Brief: Nicox Submits NDA For ZERVIATE In China For Potential Launch In 2024
14/04/2023 06:34
April 14 (Reuters) - Nicox SA NCOX.PA :
* ADDITIONAL FUTURE ROYALTY REVENUE STREAM FOR NICOX FROM
2024
FOLLOWING NEW DRUG APPLICATION SUBMISSION FOR ZERVIATE IN CHINA
* HAS SUBMITTED A NEW DRUG APPLICATION (NDA) FOR APPROVAL TO
COMMERCIALIZE ZERVIATE
* ADDITIONAL FUTURE ROYALTY REVENUE STREAM FOR NICOX WITH
OCUMENSION FORECASTING POTENTIAL ANNUAL NET SALES OF >$100
MILLION WITHIN 7 YEAR
* ZERVIATE APPROVAL AND LAUNCH EXPECTED IN CHINA IN 2024
Source text for Eikon: ID:nGNX5ykgzC
Further company coverage: NCOX.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))